Drugs / B/HPIV3/HMPV-F-B365
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06546423 Comparator | Jul 2024 → Jun 2025 | parainfluenza virus type 3 infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B/HPIV3/HMPV-F-B365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546423 ↗ |
| Modality | Vaccine | “B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate.” NCT06546423 ↗ |
| Route | Intranasal | “A single dose of intranasal B/HPIV3/HMPV-F-B365 will be administered by a Vax300 VaxINator atomization device.” NCT06546423 ↗ |